Literature DB >> 17180517

Unresectable gastric cancer with multiple liver metastases effectively treated with combined paclitaxel and doxifluridine chemotherapy.

Shin Mizutani1, Tsukasa Oyama, Nobutaka Hatanaka, Fumihiro Uchikoshi, Katsuhide Yoshidome, Masayuki Tori, Shigeyuki Ueshima, Masaaki Nakahara, Kazuyasu Nakao.   

Abstract

We report a 72-year-old man who was diagnosed by gastroscopy as having a type III poorly differentiated adenocarcinoma in the lesser curvature, with the longest diameter being 10 cm. An abdominal computed tomography (CT) scan revealed multiple liver metastases, thickening of the gastric wall, and an enlarged paraaortic lymph node. The serum carcinoembryonic antigen (CEA) level was 60 ng/ml and the carbohydrate antigen (CA) 19-9 level was 1355 U/ml. The patient received combined chemotherapy with doxifluridine (800 mg/body per day) and paclitaxel (one course comprised three weekly infusions at a dose of 70 mg/m(2) followed by 1-week rest). After the completion of three courses, the patient achieved a complete response (CR), with complete disappearance of the primary tumor, the metastatic foci in the liver, and the enlarged abdominal lymph nodes; as well, the tumor markers were normalized. Adverse effects included only mild anorexia that was limited to grade 1. He maintained a CR for 1 year and 2 months. Combination chemotherapy with paclitaxel and doxifluridine can be an effective treatment for unresectable advanced gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17180517     DOI: 10.1007/s10147-006-0597-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  11 in total

1.  Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.

Authors:  K Fujimoto-Ouchi; Y Tanaka; T Tominaga
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

Authors:  N Sawada; T Ishikawa; Y Fukase; M Nishida; T Yoshikubo; H Ishitsuka
Journal:  Clin Cancer Res       Date:  1998-04       Impact factor: 12.531

4.  Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.

Authors:  A Kono; Y Hara; S Sugata; Y Karube; Y Matsushima; H Ishitsuka
Journal:  Chem Pharm Bull (Tokyo)       Date:  1983-01       Impact factor: 1.645

5.  A combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients.

Authors:  Izumi Takeyoshi; Fujio Makita; Yoshifumi Tanahashi; Tadahiro Yokomori; Shigeru Iwazaki; Yoshiyuki Kawashima; Kotaro Iwanami; Tatsuya Yamada; Susumu Kawate; Kunihiro Hamada; Yutaka Sunose; Miho Yoshida; Jun Horiguchi; Hiroshi Iesato; Mitsunobu Kobayashi; Yasuo Morishita
Journal:  Anticancer Res       Date:  2005 Mar-Apr       Impact factor: 2.480

6.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins.

Authors:  P B Schiff; S B Horwitz
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

Review 7.  Weekly paclitaxel for a patient with advanced gastric cancer.

Authors:  Shigetaka Yamamoto; Yasuhiro Tanaka; Toshinori Ito; Toyokazu Aono; Yoshikazu Morimoto; Toru Kitagawa; Youjirou Kurihara
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

8.  Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.

Authors:  Per Rosenberg; Håkan Andersson; Karin Boman; Mona Ridderheim; Bengt Sorbe; Ulla Puistola; Gunnar Parö
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

9.  Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma.

Authors:  Yoichi Sakurai; Ikuo Yoshida; Shuhei Tonomura; Wakana Sakai; Yasuko Nakamura; Hiroki Imazu; Toshiki Matsubara; Masahiro Ochiai
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

Review 10.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

Authors:  A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

View more
  2 in total

1.  Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case.

Authors:  Joong-Min Park; Kyong-Choun Chi
Journal:  World J Surg Oncol       Date:  2010-12-20       Impact factor: 2.754

2.  Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases.

Authors:  Kenji Ina; Ryuichi Furuta; Takae Kataoka; Satoshi Kayukawa; Hiroko Ina; Masahiko Yoneda
Journal:  Med Sci (Basel)       Date:  2016-04-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.